ArticleInfectious microbes & diseases2025
Indirect ELISAs Based on Nipah and Langya Virus Proteins for Detecting Antibodies in Animals.
Article in Infectious microbes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Development and Qualification of a Nipah Virus Glycoprotein-Specific IgG ELISA for the Assessment of Human Antibody Responses.Vaccines · 2026Article
- A risk-gate mechanistic-ecological framework for assessing emergence potential of henipa-related viruses.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) and Langya virus (LayV) are emerging zoonotic henipaviruses with serious public health risks. However, no vaccine or drug is available for either disease. To address the persistent threats posed by NiV and LayV, we preliminarily developed indirect ELISAs based on truncated fusion glycoprotein (F) and attachment glycoprotein (G) expressed in a mammalian expression system. We validated these assays using immunized BALB/c mice (for both NiV and LayV), immunized Syrian golden hamsters (for NiV), and goats and a dog that were naturally infected (for LayV). Specificity was assessed using negative sera from mice, ferrets, African green monkeys, hamsters and swine. The ELISAs demonstrated high sensitivity (1:64,000) for both viruses in immunized BALB/c mice, high specificity (approximately 95% in mice and 100% in ferrets, African green monkeys, hamsters and swine), and strong concordance with commercial NiV ELISA kits (>93%). The NiV ELISAs were further validated using immunized Syrian golden hamsters, which had sensitivities of 1:51,200 (F-based) and 1:6400 (G-based). The LayV ELISAs successfully detected antibodies in the sera of goats and a dog naturally infected with LayV. These preliminary indirect ELISAs serve as proof-of-concept tools and may be valuable for vaccine and therapeutic development, serological surveillance studies and future diagnostic platform development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.